alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 99.2

[The CIT Group, Inc. Logo]

IMMEDIATE RELEASE

                     CIT DECLARES REGULAR QUARTERLY DIVIDEND

      NEW YORK, New York, January 25, 2001-- The Board of Directors of The CIT
Group, Inc. (NYSE:CIT; TSE:CIT U; CGX.U) declared a regular quarterly cash
dividend of $.10 per common share for shareholders of record on Feb. 7, 2001.
The cash dividend is payable on Feb. 28, 2001.

About CIT:

     CIT is a leading, global source of financing and leasing capital for
companies in more than 30 industries. Managing more than $50 billion in assets
across a diversified portfolio, CIT is the trusted financial engine empowering
many of today's industry leaders and emerging businesses, offering vendor,
equipment, commercial, factoring, consumer and structured financing
capabilities. Founded in 1908, CIT operates extensively in the United States and
Canada with strategic locations in Europe, Latin and South America, and the
Pacific Rim. For more information on CIT, visit the Web site at www.cit.com.

                                       ###

Media Contacts                                       Investor Relations Contacts
Joan Russo                                           James J. Egan, Jr.
CIT                                                  CIT
Joan.Russo@cit.com                                   Jim.Egan@cit.com
(973) 740-5437                                       (973) 535-5911
         or                                                 or
Sammie Becker/Joseph LoBello                         Yvette K. Rudich
Stanton Crenshaw Communications                      CIT
Sbecker/jlobello@stanton-crenshaw.com                Yvette.Rudich@cit.com
 (212) 780-1900                                      (973) 597-2095
§ 524.1446 Milbemycin otic solution. ( a ) *Specifications.* Each tube contains 0.25 milliliter of a 0.1 percent solution of milbemycin oxime.
( b ) *Sponsor.* See No. 058198 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Amount.* One tube administered topically into each external ear canal.
( 2 ) *Indications for use.* For the treatment of ear mite (*Otodectes cynotis*) infestations in cats and kittens 4 weeks of age and older. Effectiveness is maintained throughout the life cycle of the ear mite.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[65 FR 13905, Mar. 15, 2000, as amended at 66 FR 13849, Mar. 8, 2001]
§ 522.2121 Spectinomycin sulfate. ( a ) *Specifications.* Each milliliter of solution contains spectinomycin sulfate tetrahydrate equivalent to 100 milligrams (mg) spectinomycin.
( b ) *Sponsor.* See Nos. 054771 and 061133 in § 510.600(c) of this chapter.
( c ) *Related tolerances.* See § 556.600 of this chapter.
( d ) *Conditions of use in cattle* — ( 1 ) *Amount.* 10 to 15 mg per kilogram of body weight at 24-hour intervals for 3 to 5 consecutive days.
( 2 ) *Indications for use.* For the treatment of bovine respiratory disease (pneumonia) associated with *Mannheimia haemolytica, Pasteurella multocida*, and *Histophilus somni.*
( 3 ) *Limitations.* Do not slaughter within 11 days of last treatment. Do not use in female dairy cattle 20 months of age or older. Use in this class of cattle may cause residues in milk. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[72 FR 31178, June 6, 2007, as amended at 79 FR 16195, Mar. 25, 2014; 88 FR 14899, Mar. 10, 2023]
```

[115th Congress Public Law 287]
[From the U.S. Government Publishing Office]

[[Page 132 STAT. 4371]]

Public Law 115-287
115th Congress

                                 An Act

 
To designate the facility of the United States Postal Service located at 
 9801 Apollo Drive in Upper Marlboro, Maryland, as the ``Wayne K. Curry 
     Post Office Building''. <<NOTE: Dec. 6, 2018 -  [H.R. 4890]>> 

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,
SECTION 1. WAYNE K. CURRY POST OFFICE BUILDING.

    (a) Designation.--The facility of the United States Postal Service 
located at 9801 Apollo Drive in Upper Marlboro, Maryland, shall be known 
and designated as the ``Wayne K. Curry Post Office Building''.
    (b) References.--Any reference in a law, map, regulation, document, 
paper, or other record of the United States to the facility referred to 
in subsection (a) shall be deemed to be a reference to the ``Wayne K. 
Curry Post Office Building''.

    Approved December 6, 2018.

LEGISLATIVE HISTORY--H.R. 4890:
---------------------------------------------------------------------------

CONGRESSIONAL RECORD, Vol. 164 (2018):
            July 16, considered and passed House.
            Nov. 15, considered and passed Senate.

                                  <all>
```
EXHIBIT 23.1.1

               CONSENT OF SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP

<PAGE>

      We consent to the reference to this firm under the heading "Risk
Factors--Future State Legislative Action May Invalidate the Transition Bonds or
Their Underlying Assets" in the Prospectus included in the Registration
Statement.

                                    Very truly yours,

                                    /s/ Skadden, Arps, Slate, Meagher & Flom LLP
F ILED U.S. COURT O F APP EALS EL EV EN TH C IRC UIT Au gust 7, 2002 T HOMA S K. KA HN CLERK [PUBLIS H]
IN THE UN ITED STATES COURT OF APPEALS
FO R T HE EL EV EN TH CIRC UI T

____ ____ ____ ____ ____ N o. 01- 1360 6

____ ____ ____ ____ ____ _ D. C. Dock et No. 9 9- 00 04 2- CV-WLS
W ILLIE SANTONIO MANDERS, Plaintiff-Appellee,

ve rs us T H U RM A

N L E E , ind ivi dua lly

a nd a s e m

plo y ee of the Ci ty of H om er vil le , A L A

N BR O W N , ind ivi dua lly

a nd as em ploy ee of the C ity

of H om erville, BAR T C RE W S, indiv iduallyand as em

ploy ee of the C ity

of Hom erv il le , CITY OF HOMERVILLE, CLINCH COUNTY, GEORGIA,
D ef en da nts , W IN ST O N P E T E RS O N , ind ivi dua lly a nd a s e m

plo y ee of Cl in ch Co un ty, Geo rg ia , D ef en da nt- A ppe llant.

____ ____ ____ ____ ___ A ppe al f ro m the U nit ed

S ta te s D ist ri ct

Co urt fo r the Mi ddl e D ist ri ct

of G eo rg ia

____ ____ ____ ____ ____ _ (A ugus t 7, 200 2) (O pinio n March 14, 2002, 285 F. 3d 98 3) Befo re EDMONDSON, Ch i e f J ud ge , and TJOFLAT, ANDERSON, BIRCH, D U BI N A , BL A CK , CA RN E S, BA RK E T T , H U L L , MA RC U S an d W I L S O N , Ci rc uit Judg es
.2

BY THE COURT:
A m em be r of thi s C ourt i n a ctiv e se rv ic e hav ing r eque ste d apol l on the
sugg es tio n of

r eh ea ri ng e n ba nc a nd a

m aj or ity of the j udge s inthi s C ourt in a ct ive service having voted in favor of granting a rehearing en banc,
IT IS O RDE RE D that the above cause shall be rehear d by this court en banc. The pre vi ou s p an el 's o pi ni on is he reb y VACATED.
IN THE SUPREME COURT OF PENNSYLVANIA

EASTERN DISTRICT

COMMONWEALTH OF PENNSYLVANIA,

Respondent

v.

OMAR RODRIGUEZ,

Petitioner

:

:

:

:

:

:

:

:

:

:

:

No. 133 EAL 2017

Petition for Allowance of Appeal from 

the Order of the Superior Court

ORDER

PER CURIAM

AND NOW, this 8th day of August, 2017, the Petition for Allowance of Appeal is 

DENIED.
- All
            - Title
            - Author
            - Subject
            - Date
            - Full-Text

            -                              Explore                            ******                - Educational Resources
              - Archival Collections
              -                                      Themes                                    ******                  - Economic Data
                - Federal Reserve
                - View all 
              - Timelines 
            -                              Browse                            ******                - Titles
              - Authors
              - Subjects
              - Dates 
            -                              About                            ******                - About FRASER
              - FAQ
              - Contact Us
              -                                      FRASER API                                    ******                  - REST API
                - OAI-PMH 
            - Inside FRASER Blog

            - **

Home                 > Browse by Title > Activities of Consumers' Cooperatives in 1942

              																	United States. Bureau of Labor Statistics. 						*Activities of Consumers' Cooperatives in 1942 : Bulletin of the United States Bureau of Labor Statistics, No. 757*,												Washington, D.C: 								G.P.O., 										1943,									https://fraser.stlouisfed.org/title/4242,			accessed on September 25, 2024.						    

        - **FRASER**
        - About
        - FAQ
        - Legal and Privacy
        - FRASER API

          -                              @FedFRASER 
          - ** Contact Us
          -  **  What's New  
          -  **  Inside FRASER
p. 1 

# OAR Box 1877 Prepped byKeeia Richards



### Document

Number: 

# 38 ) ll-B-3 5 Docket Number: 

# A-90-1 9

Printed 12/2/200810:36:49AM

Sheet 38of 46P. 2 

# A-90-1 9 ll-B-3 5 

# PENDINGCONFIDENTIA L

Th e following informatio n i s locate d in th e confidentia l file s o f th e Director , Emissio n Standard s Division , Offic e o f Ai r Qualit yPlanning an d Standards , U . S . Environmenta l Protectio n Agency , Researc hTriangl e Park , Nort hCarolina 27711 . Thi s informatio n i s confidentia l pending fina l determinatio n b yth e Administrato r an

d i s no t availabl e fo r publi c inspection . W . Floyd , Radia n Corporation , t o Proces s Vent s Docke t A-90-19 , Decembe r 1990 , HO NNESHAP : Industr

y Characteristics/Chlorotrifluoromethane . 2 5 pages . CB I Documen t Contro l No . 86/23 , PPS-35 .



# ojJLiUL .
<PAGE>   1
                                                                    Exhibit 23.2



                        Consent of Independent Auditors


We consent to the incorporation by reference in this Annual Report (Form 10-K)
of Smartflex systems, Inc. of our report dated February 7, 1997, included in
the 1996 Annual Report to Shareholders of Smartflex Systems, Inc.

Our audits also included the financial statement schedule of Smartflex Systems,
Inc., listed in the Index at Item 14(a).  This schedule is the responsibility
of the Company's management.  Our responsibility is to express an opinion based
on our audits.  In our opinion, such consolidted financial statement schedule
referred to above, when considered in relation to the basic consolidated
financial statements taken as a whole, presents fairly in all material respects
the information set forth therein.

We also consent to the incorporation by reference in the Registration Statement
(Form S-8 No. 33-95434) pertaining to the 1995 Equity Incentive Plan of
Smartflex Systems, Inc., the Registration statement (Form S-8 No. 33-95358)
pertaining to the 1995 Employee Stock Purchase Plan of Smartflex Systems, Inc.
and the Registration Statement (Form S-8 No. 33-95372) pertaining to the 1993
Equity Incentive Plan of Smartflex Systems, Inc. of our report dated February
7, 1997 with respect to the consolidated financial statements incorporated
herein by reference, and our report included in the preceding paragraph with
respect to the financial statement schedule included in this Annual Report
(Form 10-K) of Smartflex Systems, Inc.


                                                           /s/ Ernst & Young LLP


Orange County, California
March 26, 1997
#### JURAGUA IRON COMPANY v. THE UNITED STATES.

[42 C. Cls. R., 99; 212 U. S. R., 297.]

*On the claimant's Appeal.*

An American corporation, having its principal place of business in Philadelphia, becomes the owner of real and personal property-in Cuba prior to the war with Spain. During the war buildings thereon are destroyed under proper military authority to preserve the health of troops encamped near them and to prevent the spreading of yellow fever. Certain railroad cars belonging to the claimant are taken and used in the operations of the army during the war and impaired and destroyed.

*596The court below decides:

I.The law is well settled that where a citizen of one belligerent is engaged in business within the territory of the other owning property, which has a permanent situs, it is subject to the same treatment as that of the enemy.

II.A belligerent in enemy’s country has the right under the usages of modern warfare to destroy property for the protection of • his troops against the ravages of disease.

III.A belligerent power is not liable for the destruction of property belonging to its own citizens If the destruction be caused by military operations.

The decision of the court below is affirmed.

Mr. Justice Harlan delivered the opinion of the Supreme Court February 23, 1909.
csgs-ex1025ck_121.htm



Pages where confidential treatment has been requested are stamped “Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission,” and places where information has been redacted have been marked with (***). 

Exhibit10.25CK

 

 

NINETY-EIGHTH AMENDMENT

TO THE

AMENDED AND RESTATED

CSG MASTER SUBSCRIBER MANAGEMENT SYSTEM AGREEMENT

BETWEEN

csg SYSTEMS, INC.

AND

CHARTER COMMUNICATIONS HOLDING COMPANY, LLC

 

 

 

This NINETY-EIGHTH AMENDMENT (the “Amendment”) is made by and between CSG Systems, Inc. (“CSG”) and Charter Communications Holding Company, LLC (“Customer”).  The effective date of this Amendment is the date last signed below (the "Effective Date").  CSG and Customer entered into that certain Amended and Restated CSG Master Subscriber Management System Agreement (CSG document no. 2298875) dated February 9, 2009, as amended (the “Agreement”), and now desire to further amend the Agreement in accordance with the terms and conditions set forth in this Amendment.  If the terms and conditions set forth in this Amendment shall be in conflict with the Agreement, the terms and conditions of this Amendment shall control.  Any terms in initial capital letters or all capital letters used as a defined term but not defined in this Amendment shall have the meaning set forth in the Agreement.  Upon execution of this Amendment by the Parties, any subsequent reference to the Agreement between the Parties shall mean the Agreement as amended by this Amendment.  Except as amended by this Amendment, the terms and conditions set forth in the Agreement shall continue in full force and effect according to their terms. 

 

1.    Customer desires to use and CSG agrees to provide Customer with an additional *** ******* *********** (***) Web Enabled Advanced Customer Service Representative® (Web Enabled ACSR®) licenses pursuant to the terms and conditions of the Agreement.  As a result, for the fees set forth in Schedule F to the Agreement, the number of Customer’s Web Enabled ACSR® licenses shall increase such that the total of Customer’s Web Enabled ACSR® licenses is **** ******* *********** (***).  

 

IN WITNESS WHEREOF the parties hereto have caused this Amendment to be executed by their duly authorized representatives.

 


		
	
CHARTER COMMUNICATIONS HOLDING COMPANY, LLC (“CUSTOMER”)

 

By: Charter Communications, Inc., its Manager
	
CSG SYSTEMS, INC. (“CSG”)

	
 

By: /s/ Mike Ciszek
	
 

By:  /s/ Gregory L. Cannon

	
 

Name:  Mike Ciszek
	
 

Name:  Gregory L. Cannon

	
 

Title:  SVP, Billing Strat & Opns
	
 

Title:  SVP, General Counsel & Secretary

	
 

Date:  1-20-17
	
 

Date:  1/23/17
# C_2014135EN.01001802.xml

| 5.5.2014 | EN | Official Journal of the European Union | C 135/18 |
| --- | --- | --- | --- |

5.5.2014

EN

Official Journal of the European Union

C 135/18

---

Request for a preliminary ruling from the Hoge Raad der Nederlanden (Netherlands) lodged on 22 January 2014 — Ryanair Ltd, Other party: PR Aviation BV

(Case C-30/14)

2014/C 135/20

Language of the case: Dutch

Referring court

Referring court

Hoge Raad der Nederlanden

Parties to the main proceedings

Parties to the main proceedings

Applicant: Ryanair Ltd

Applicant:

Other party: PR Aviation BV

Other party:

Question referred

Question referred

Does the operation of the [Database Directive] (1) also extend to online databases which are not protected by copyright on the basis of Chapter II of the Directive, and also not by a sui generis right on the basis of Chapter III, in the sense that the freedom to use such databases through the (whether or not analogous) application of Articles 6(1) and 8 in conjunction with Article 15 [of the Database Directive], may not be limited contractually?

1

---

(1)  Directive 96/9/EC of the European Parliament and of the Council of 11 March 1996 on the legal protection of databases (OJ 1996 L 77, p. 20).

1

---
# Materials Not Included in

Airworthiness Directive (AD) Docket

Docket Number: FAA

- 2014

- 0774

Directorate Identifier: 2013NM154AD

747

- 53A2562, R2

--- 5/31/07

Name/Description of Item(s) Not Included in FDMS Docket and Maintained in the

Supplemental AD Docket



### MAY BE VIEWED AT: Federal Aviation Administration

Transport Airplane Directorate

Rules Docket

1601 Lind Ave. SW.,

Renton, WA 98057

425.227.1221

DURING THE HOURS OF: 9 a.m. and 3 p.m., Monday through Friday,

except Federal holidays.

Form Date: 03/05/2008
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                          <C>
<PERIOD-TYPE>                9-MOS
<FISCAL-YEAR-END>                         MAY-31-1997
<PERIOD-END>                              FEB-28-1998
<CASH>                                             635,046
<SECURITIES>                                             0
<RECEIVABLES>                                    1,754,396
<ALLOWANCES>                                      (109,539)
<INVENTORY>                                        791,980
<CURRENT-ASSETS>                                 3,255,177
<PP&E>                                           4,765,175
<DEPRECIATION>                                    (498,080)
<TOTAL-ASSETS>                                   8,234,964
<CURRENT-LIABILITIES>                            3,320,867
<BONDS>                                          1,841,330
<PREFERRED-MANDATORY>                                    0
<PREFERRED>                                              0
<COMMON>                                            15,444
<OTHER-SE>                                       2,868,360
<TOTAL-LIABILITY-AND-EQUITY>                     8,234,964
<SALES>                                         14,583,786
<TOTAL-REVENUES>                                14,583,786
<CGS>                                           11,864,971
<TOTAL-COSTS>                                   16,009,413
<OTHER-EXPENSES>                                   (22,886)
<LOSS-PROVISION>                                         0
<INTEREST-EXPENSE>                                 127,502
<INCOME-PRETAX>                                 (1,530,243)
<INCOME-TAX>                                       (39,969)
<INCOME-CONTINUING>                             (1,490,274)
<DISCONTINUED>                                           0
<EXTRAORDINARY>                                          0
<CHANGES>                                                0
<NET-INCOME>                                    (1,490,274)
<EPS-PRIMARY>                                        (0.96)
<EPS-DILUTED>                                        (0.96)
        

</TABLE>
§ 516.52 Availability for public disclosure of data and information in requests. ( a ) FDA will not publicly disclose the existence of a request for MUMS-drug designation under section 573 of the act prior to final FDA action on the request unless the existence of the request has been previously publicly disclosed or acknowledged.
( b ) Whether or not the existence of a pending request for designation has been publicly disclosed or acknowledged, no data or information in the request are available for public disclosure prior to final FDA action on the request.
( c ) Except as provided in paragraph (d) of this section, upon final FDA action on a request for designation, the public availability of data and information in the request will be determined in accordance with part 20 of this chapter and other applicable statutes and regulations.
( d ) In accordance with § 516.28, FDA will make a cumulative list of all MUMS-drug designations available to the public and update such list periodically. In accordance with § 516.29, FDA will give public notice of the termination of all MUMS-drug designations.
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1409 Ground limestone. ( a ) Ground limestone consists essentially (not less than 94 percent) of calcium carbonate (CaCO3) and is prepared by the crushing, grinding, and classifying of naturally occurring limestone.
( b ) The ingredient meets the specifications of the Food Chemicals Codex, 3d Ed. (1981), p. 173, which is incorporated by reference. Copies are available from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or available for inspection at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitation other than current good manufacturing practice.
( d ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[48 FR 52442, Nov. 18, 1983]
Editorial Note on Part 170
Editorial Note: Nomenclature changes to part 170 appear at 66 FR 56035, Nov. 6, 2001, and 69 FR 13717, Mar. 24, 2004.

§ 170.250 Part 6 of a GRAS notice: Narrative. In Part 6 of your GRAS notice, you must include a narrative that provides the basis for your conclusion of GRAS status, in which: ( a ) ( 1 ) You must explain why the data and information in your notice provide a basis for your view that the notified substance is safe under the conditions of its intended use. In your explanation, you must address the safety of the notified substance, considering all dietary sources and taking into account any chemically or pharmacologically related substances in such diet;
( 2 ) In your explanation, you must identify what specific data and information that you discuss in accordance with paragraph (a)(1) of this section are generally available, and what specific data and information that you discuss in accordance with paragraph (a)(1) of this section are not generally available, by providing citations to the list of data and information that you include in Part 7 of your GRAS notice in accordance with § 170.255;
( b ) You must explain how the generally available data and information that you rely on to establish safety in accordance with paragraph (a) of this section provide a basis for your conclusion that the notified substance is generally recognized, among qualified experts, to be safe under the conditions of its intended use;
( c ) You must either: ( 1 ) Identify, discuss, and place in context, data and information that are, or may appear to be, inconsistent with your conclusion of GRAS status, regardless of whether those data and information are generally available; or
( 2 ) State that you have reviewed the available data and information and are not aware of any data and information that are, or may appear to be, inconsistent with your conclusion of GRAS status;
( d ) If you view any of the data and information in your notice as exempt from disclosure under the Freedom of Information Act, you must identify the specific data and information; and
( e ) For non-public, safety-related data and information considered in reaching a conclusion of GRAS status, you must explain how there could be a basis for a conclusion of GRAS status if qualified experts do not have access to such data and information.